Arcadia Biosciences, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed July 2, 2026 reports Items 5.02 (director/officer departure and compensation arrangements) and 5.08 (shareholder nominations). The filing does not disclose specific names, dollar amounts, dates of departure, or details of any compensation arrangements or nomination specifics in the provided text excerpt.
Why this rating
Leadership/board changes are routine disclosures; specifics absent. At $5.7M market cap, even modest executive turnover is manageable absent major business disruption or financial impact details.
Extracted items
- 5.02 exec change
- 5.08
- 8.01 other event
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.